Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PKLR | P30613 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14185682 | 1.00 | HTR6 (0.54) | HTR6DRD2PKMPKLRADRA2A | |
| SCHEMBL14185679 | 0.96 | HTR6 (0.52) | HTR6DRD2PKMPKLRADRA2A | |
| SCHEMBL3144111 | 0.96 | HTR6 (0.52) | HTR6DRD2PKMPKLRADRA2A | |
| SCHEMBL14185683 | 0.94 | HTR6 (0.50) | HTR6DRD2PKMPKLRADRA2A | |
| SCHEMBL3154311 | 0.94 | HTR6 (0.50) | HTR6DRD2PKMPKLRADRA2A | |
| SCHEMBL14185693 | 0.89 | HTR6 (0.67) | HTR6DRD2ADRA2AADRA2BADRA2C | |
| SCHEMBL3144243 | 0.89 | HTR6 (0.67) | HTR6DRD2ADRA2AADRA2BADRA2C | |
| SCHEMBL1136529 | 0.85 | HTR6 (0.57) | HTR6PKMPKLRMAPK1 | |
| SCHEMBL3148891 | 0.85 | HTR6 (0.66) | HTR6DRD2ADRA2AADRA2BADRA2C | |
| SCHEMBL3150125 | 0.84 | HTR6 (0.65) | HTR6DRD2ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1748995-B1 | ARYLSULFONYL BENZODIOXANES USEFUL FOR MODULATION THE 5-HT6 RECEPTOR, THE 5-HT2ARECEPTOR OR BOTH | HOFFMANN LA ROCHE (CH) | 2010-02-24 | — | — | EP | claimed |
| CN-100540546-C | Be used to regulate 5-HT6 acceptor, 5-HT2A acceptor or both aryl sulfonyl benzos two alkane | HOFFMANN LA ROCHE (CH) | 2009-09-16 | — | — | CN | claimed |
| US-7368567-B2 | Arylsulfonyl benzodioxanes, benzoxazines and benzothiazines as 5-HT6 antagonists | ROCHE PALO ALTO LLC (US) | 2008-05-06 | — | — | US | claimed |
| CN-1960983-A | Arylsulfonyl benzodioxanes useful for modulation the 5-HT6 receptor, the 5-HT2areceptor or both | HOFFMANN LA ROCHE (CH) | 2007-05-09 | — | — | CN | claimed |
| EP-1748995-A1 | ARYLSULFONYL BENZODIOXANES USEFUL FOR MODULATION THE 5-HT6 RECEPTOR, THE 5-HT2ARECEPTOR OR BOTH | F. Hoffmann-La Roche AG (CH) | 2007-02-07 | — | — | EP | claimed |
| WO-2005105776-A1 | ARYLSULFONYL BENZODIOXANES USEFUL FOR MODULATION THE 5-HT6 RECEPTOR, THE 5-HT2ARECEPTOR OR BOTH | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-10 | — | — | WO | claimed |
| US-20050250943-A1 | Arylsulfonyl benzodioxanes, benzoxazines and benzothiazines as 5-HT6 antagonists | ROCHE PALO ALTO LLC | 2005-11-10 | — | — | US | claimed |
| EP-1748995-B1 | ARYLSULFONYL BENZODIOXANES USEFUL FOR MODULATION THE 5-HT6 RECEPTOR, THE 5-HT2ARECEPTOR OR BOTH | HOFFMANN LA ROCHE (CH) | 2010-02-24 | — | — | EP | disclosed |
| CN-100540546-C | Be used to regulate 5-HT6 acceptor, 5-HT2A acceptor or both aryl sulfonyl benzos two alkane | HOFFMANN LA ROCHE (CH) | 2009-09-16 | — | — | CN | disclosed |
| US-7368567-B2 | Arylsulfonyl benzodioxanes, benzoxazines and benzothiazines as 5-HT6 antagonists | ROCHE PALO ALTO LLC (US) | 2008-05-06 | — | — | US | disclosed |
| CN-1960983-A | Arylsulfonyl benzodioxanes useful for modulation the 5-HT6 receptor, the 5-HT2areceptor or both | HOFFMANN LA ROCHE (CH) | 2007-05-09 | — | — | CN | disclosed |
| US-20050250943-A1 | Arylsulfonyl benzodioxanes, benzoxazines and benzothiazines as 5-HT6 antagonists | ROCHE PALO ALTO LLC | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250943-A1 | Arylsulfonyl benzodioxanes, benzoxazines and benzothiazines as 5-HT6 antagonists | HTR6, HTR7, HTR1F | HTR6 1/4885DRD2 152/4885PKM 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.